secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-106913
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio Q2 cash $187.4M, R&D $6.6M; budoprutug trials underway; new CMO
-------------------------------------------------------------------------

- Cash and marketable securities $187.4M as of June 30, 2025; cash runway expected through 2027.
- R&D expenses $6.6M in Q2 2025 vs $1.0M in Q2 2024; no acquired IPR&D expense in 2025.
- Budoprutug ITP and SLE trials dosing patients; pMN Phase 2 to initiate; SC formulation Phase 1 data expected H1 2026.
- CLYM116 investor event September 2025 with preclinical data; IND/CTA for IgAN expected H2 2025.
- Edgar D. Charles, M.D., MSc appointed CMO, joining from Bristol Myers Squibb in June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/0000950170-25-106913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/clym-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer